Broadly neutralizing humanized SARS-CoV-2 antibody binds to a conserved epitope on Spike and provides antiviral protection through inhalation-based delivery in non-human primates.

导出 OA

翻译打印收藏纠错

作者： Paule,Hermet ^[1] ; Benoît,Delache ^[2] ; Cecile,Herate ^[2] ; Esther,Wolf ^[3] ; Gaily,Kivi ^[1] ; Erkki,Juronen ^[1] ; Karl,Mumm ^[1] ; Eva,Žusinaite ^[4] ; Denis,Kainov ^[5] ; Eve,Sankovski ^[1] ; Kai,Virumäe ^[1] ; Anu,Planken ^[1] ; Andres,Merits ^[4] ; Jessica E,Besaw ^[6] ; Ai Woon,Yee ^[6] ; Takefumi,Morizumi ^[6] ; Kyumhyuk,Kim ^[6] ; Anling,Kuo ^[6] ; Asma,Berriche ^[2] ; Nathalie,Dereuddre-Bosquet ^[2] ; Quentin,Sconosciuti ^[2] ; Thibaut,Naninck ^[2] ; Francis,Relouzat ^[2] ; Mariangela,Cavarelli ^[2] ; Mart,Ustav ^[1] ; Derek,Wilson ^[3] ; Oliver P,Ernst ^[6] ; Andres,Männik ^[7] ; Roger,LeGrand ^[1] ; Mart,Ustav ^[2]

作者单位： Icosagen Cell Factory OÜ; Tartu, Estonia. ^[1] Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT); Fontenay-aux-Roses, France. ^[2] York University; Toronto, Canada. ^[3] University of Tartu; Tartu, Estonia. ^[4] NTNU; Trondheim, Norway. ^[5] Department of Biochemistry, University of Toronto; Toronto, Canada. ^[6] Department of Molecular Genetics, University of Toronto; Toronto, Canada. ^[7]